The Increasing Cancer Incidence Is Fueling The Growth Of The Market Due To Its Rising Prevalence And Demand For Targeted Therapies Is Supporting Development Across The Radioligand Therapy Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Radioligand Therapy Market?

The radioligand therapy market size has seen rapid growth in recent years. It is expected to grow from $6.63 billion in 2025 to $7.32 billion in 2026, with a compound annual growth rate (CAGR) of 10.4%. The expansion observed in the past can be attributed to factors such as the limited accessibility of radioligands, the previous reliance on conventional cancer treatments, an increasing understanding of the benefits of targeted therapies, the rising adoption of nuclear medicine techniques in hospitals, and the initial regulatory approvals for RLT drugs.

The radioligand therapy market is projected for significant expansion over the coming years, with its valuation reaching $10.72 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by factors such as the development of new alpha and beta emitters, the broadening of combined emission therapies, their integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and greater investment in home care and outpatient radioligand therapy services. Key trends expected during this period involve the growing acceptance of targeted radioligand therapy for cancer treatment, the expansion of therapies utilizing alpha and beta emitters, the integration of radioligand therapy with personalized medicine strategies, an increase in radioligand therapy programs within hospitals and research institutions, and a heightened emphasis on reducing adverse effects while improving patient results.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Drivers Are Advancing The Radioligand Therapy Market Growth?

The future expansion of the radioligand therapy market is anticipated to be driven by the rising occurrence of cancer. This condition, cancer, is characterized by the unchecked proliferation of atypical cells capable of infiltrating adjacent tissues and disseminating across the body. The surge in cancer cases stems from prolonged exposure to environmental contaminants, which harm DNA, impair cellular processes, and stimulate the development of irregular cell growth. Radioligand therapy offers a treatment for cancer by precisely delivering radiation to tumor cells. It achieves this through ligands that attach to specific receptors, thereby limiting damage to healthy tissues while internally eliminating cancer cells. As an illustration, data from October 2025 by the National Health Service (NHS), a government health agency in the UK, revealed 354,820 new cancer diagnoses in 2023, averaging 972 daily. This figure represents an increase of 8,605 compared to 2022. Consequently, the escalating rate of cancer incidence is a primary factor fueling the expansion of the radioligand therapy market.

Which Segment Divisions Form The Structure Of The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Trends Are Shaping The Radioligand Therapy Market Structure?

Leading companies in the radioligand therapy market are focused on developing advanced solutions, such as radioligand therapy facilities, to improve production efficiency and uphold consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers crafted to handle and deliver radioactive medications for precise cancer treatment, utilizing advanced imaging systems and radiation shielding, while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Which Key Players Are Active In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc.

Access The Complete Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Holds The Largest Share In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Radioligand Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795